Revolution Medicines (NASDAQ:RVMDW – Get Free Report) is expected to be announcing its results after the market closes on Wednesday, November 4th. Analysts expect Revolution Medicines to post earnings of ($2.3451) per share and revenue of $25.58 million for the quarter.
Revolution Medicines Stock Down 0.5%
Shares of NASDAQ RVMDW traded down $0.05 during mid-day trading on Wednesday, hitting $9.27. The company had a trading volume of 129 shares, compared to its average volume of 95,627. Revolution Medicines has a 12 month low of $0.34 and a 12 month high of $13.44. The business’s 50-day simple moving average is $10.85 and its 200-day simple moving average is $6.52.
About Revolution Medicines
Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company’s research is centered on the RAS signaling pathway, which is frequently altered in tumors and has historically been difficult to target with medicines.
Revolution Medicines is developing a pipeline of RAS(ON) inhibitors designed to block active RAS proteins and related signaling. Its investigational programs include daraxonrasib (RMC-6236), an oral, broad-spectrum RAS(ON) inhibitor, as well as mutation-selective candidates such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C.
See Also
- Five stocks we like better than Revolution Medicines
- Palantir’s Q3 Bar Is Higher Than It Looks: 3 Numbers to Watch
- Johnson Controls Beats the Heat in AI Data Centers
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
- Is United Parcel Service Finally Turning the Corner?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
